CVS
CVS HEALTH CorpPrice & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Days claims payable | 42.9 | As of March 31, 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CVS
this stock
CVS HEALTH Corp
|
$133.62B | +33.0% | +10.9% | 45.9 | 1.8% |
|
UNH
Unitedhealth Group Inc
|
$386.29B | +29.9% | +11.8% | 32.0 | 1.9% |
|
ELV
Elevance Health, Inc.
|
$90.75B | +19.9% | +9.4% | 17.7 | 2.9% |
|
CI
Cigna Group
|
$76.12B | +5.1% | +11.2% | 12.2 | 2.8% |
|
HUM
Humana Inc
|
$47.63B | +55.7% | +10.1% | 42.3 | 5.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CVS | +0.1% | +14.6% | +31.0% | +1.2% | +33.0% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -1.4% | +15.9% | +23.0% | +1.5% | +23.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.